Last $1.79 USD
Change Today -0.14 / -7.25%
Volume 50.9K
PDII On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

pdi inc (PDII) Snapshot

Open
$1.86
Previous Close
$1.93
Day High
$1.99
Day Low
$1.76
52 Week High
04/22/14 - $5.44
52 Week Low
01/16/15 - $1.30
Market Cap
27.5M
Average Volume 10 Days
57.3K
EPS TTM
$-0.82
Shares Outstanding
15.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PDI INC (PDII)

pdi inc (PDII) Related Bloomberg News

View More Bloomberg News

pdi inc (PDII) Related Businessweek News

No Related Businessweek News Found

pdi inc (PDII) Details

PDI, Inc. provides outsourced commercial services to pharmaceutical, biotechnology, and healthcare companies in the United States. The company’s services offer customers a range of personal and non-personal promotional options for the commercialization of their products throughout the product lifecycles, from development through maturity. It operates in three segments: Sales Services, Marketing Services, and Product Commercialization Services. The Sales Services segment focuses primarily on product detailing, which includes a sales representative meeting face-to-face with targeted physicians and other healthcare decision makers to provide a technical review of the product being promoted and deliver marketing materials, including samples. It also offers a portfolio of sales services consisting of talent acquisition services, short-term teams, and vacancy coverage services. The Marketing Services segment is involved in the creation, design, and implementation of interactive digital communications programs to the healthcare community through the Internet, multimedia, tablet PCs, mobile devices, and dimensional direct mails, as well as DIAGRAM, a proprietary software to deliver digital selling solutions through interactive communications exchanges that accommodate the schedules of healthcare providers. This segment is also engaged in the creation of teledetailing programs executed through tele-representatives. The Product Commercialization Services segment provides product commercialization solutions, including product distribution, product detailing, full supply chain management, operations, sales, marketing, compliance, and regulatory/medical management to pharmaceutical, biotechnology, medical device, and diagnostics clients. PDI, Inc. has a strategic collaboration agreement with Transgenomic, Inc. The company was founded in 1987 and is headquartered in Parsippany, New Jersey.

706 Employees
Last Reported Date: 03/6/14
Founded in 1987

pdi inc (PDII) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.0M
President of Sales Services
Total Annual Compensation: $488.5K
Compensation as of Fiscal Year 2013.

pdi inc (PDII) Key Developments

PDI, Inc. Announces Publication of Results of the Pivotal PancraGen Multicenter Clinical Validation

PDI, Inc. announced the publication of results of the pivotal PancraGen multicenter clinical validation study in the February 2015 issue of Endoscopy. The study concluded that PancraGen (formerly PathFinderTG®-Pancreas) is 90% accurate at predicting benign and malignant disease in patients with pancreatic cysts, providing important insights into patients' likelihood of pancreatic cancer. These results provide support for using PancraGen to provide more informed management decisions for patients with pancreatic cysts, including whether surgery or surveillance is the most appropriate approach. Due to the limitations of standard first-line tests, up to 80% of surgeries on pancreatic cyst patients are potentially unnecessary. Such overtreatment can cause lifelong consequences to patients, including diabetes. The results of the Endoscopy study show that use of PancraGen can help physicians more effectively determine which cysts have low versus high risk of malignancy, providing significant improvements in patient risk stratification compared to approaches recommended by current patient management guidelines.

PDI Inc. Re-Affirms Earnings Guidance for the Year 2014

PDI Inc. re-affirmed earnings guidance For the year 2014. For the year, the company expects an operating loss of $15 million to $17 million on a GAAP-basis, with revenues of $121 million to $123 million.

SWK Funding LLC Enters into Credit Agreement with PDI, Inc

On October 31, 2014, SWK Funding LLC entered into a credit agreement among pursuant to which the company provided to PDI, Inc. a term loan in the principal amount of $20,000,000. The loan matures on October 31, 2020. The loan bears interest at the greater of three month LIBOR and 1.0%, plus a margin of 12.5%, payable in cash quarterly in arrears, beginning on February 17, 2015. The interest rate will be increased by 3.0% in the event of a default under the credit agreement. Interest and principal under the loan will be paid by a tiered revenue interest that is charged on quarterly net sales and royalties of the borrower applied in the following priority first, to the payment of all accrued but unpaid interest until paid in full; second to the payment of all principal of the loans. Beginning in January 2017, the Borrower will be required to make principal payments on the loan. Additionally, beginning in January 2017 and ending on October 31, 2020, subject to a $250,000 per quarter cap, the company will be entitled to receive quarterly revenue-based payments from the Borrower equal to 1.25% of revenue derived from net sales of molecular diagnostics products.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PDII:US $1.79 USD -0.14

PDII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PDII.
View Industry Companies
 

Industry Analysis

PDII

Industry Average

Valuation PDII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.2x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PDI INC, please visit www.pdi-inc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.